Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 4Unknown 1Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Melanoma 7Colorectal Neoplasms 3Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Skin Neoplasms 1Rectal Neoplasms 1Pancreatic Neoplasms 1Neurofibromatosis 1 1Neoplasm Metastasis 1Lymphatic Metastasis 1Lung Neoplasms 1Hereditary Sensory and Autonomic Neuropathies 1Hematologic Neoplasms 1Gliosarcoma 1Glioma 1Glioblastoma 1Colonic Neoplasms 1Brain Neoplasms 1Astrocytoma 1

Interventions

pembrolizumab 30Capecitabine 24Bevacizumab 23Cyclophosphamide 22Gemcitabine 21Paclitaxel 20Nivolumab 19Fluorouracil 19Docetaxel 18aldesleukin 17Leucovorin 17Irinotecan 17Oxaliplatin 15Interleukin-2 14Radiosurgery 13Cisplatin 13Cetuximab 13fludarabine 12Carboplatin 12Albumin-Bound Paclitaxel 11fludarabine phosphate 10Ipilimumab 10Drug Therapy 10Doxorubicin 10Sunitinib 9Radiotherapy 9Everolimus 9130-nm albumin-bound paclitaxel 9Trastuzumab 8Temozolomide 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Neoplasm Metastasis × encorafenib × Clear all
NCT04585815 2026-01-09

Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)

Pfizer

Phase 1/2 Terminated
34 enrolled 44 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡